{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:24:44Z","timestamp":1789179884261,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07751-9","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:39:38Z","timestamp":1770183578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards"],"prefix":"10.1186","volume":"24","author":[{"given":"Sara","family":"Ortega-Bertran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Magall\u00f3n-Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Creus-Bachiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Uriarte-Arrazola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Mazuelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Garraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Carri\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernat","family":"Gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-5906","authenticated-orcid":false,"given":"Conxi","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"5","key":"7751_CR1","first-page":"1573","volume":"62","author":"RE Ferner","year":"2002","unstructured":"Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573\u201377.","journal-title":"Cancer Res"},{"issue":"1","key":"7751_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1245\/s10434-012-2573-2","volume":"20","author":"J LaFemina","year":"2013","unstructured":"LaFemina J, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20(1):66\u201372.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"7751_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311\u201314.","journal-title":"J Med Genet"},{"issue":"17","key":"7751_CR4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, et al. Distinctive Cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7751_CR5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","volume":"57","author":"BS Ducatman","year":"1986","unstructured":"Ducatman BS, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006\u201321.","journal-title":"Cancer"},{"key":"7751_CR6","doi-asserted-by":"crossref","unstructured":"Porter DE, et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009; 2009. p. 756395.","DOI":"10.1155\/2009\/756395"},{"key":"7751_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1750-1172-8-127","volume":"8","author":"O Zehou","year":"2013","unstructured":"Zehou O, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"7751_CR8","doi-asserted-by":"publisher","first-page":"106096","DOI":"10.1016\/j.isci.2023.106096","volume":"26","author":"M Magall\u00f3n-Lorenz","year":"2023","unstructured":"Magall\u00f3n-Lorenz M, et al. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023;26(2):106096.","journal-title":"iScience"},{"issue":"3","key":"7751_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13(3):654\u201371.","journal-title":"Cancer Discov"},{"issue":"11","key":"7751_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227\u201332.","journal-title":"Nat Genet"},{"key":"7751_CR11","doi-asserted-by":"crossref","unstructured":"Kim A, et al. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017; 2017. p. 7429697.","DOI":"10.1155\/2017\/7429697"},{"key":"7751_CR12","volume-title":"Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: new patient-derived orthotopic xenografts, cell lines and tumor entities","author":"E Creus-Bachiller","year":"2023","unstructured":"Creus-Bachiller E, et al. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: new patient-derived orthotopic xenografts, cell lines and tumor entities. Mol Oncol; 2023."},{"issue":"5","key":"7751_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.15252\/emmm.201404430","volume":"7","author":"J Castellsagu\u00e9","year":"2015","unstructured":"Castellsagu\u00e9 J, et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med. 2015;7(5):608\u201327.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"7751_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-21-0947","volume":"21","author":"J Fern\u00e1ndez-Rodr\u00edguez","year":"2022","unstructured":"Fern\u00e1ndez-Rodr\u00edguez J, et al. A high-throughput screening platform identifies novel combination treatments for malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2022;21(7):1246\u201358.","journal-title":"Mol Cancer Ther"},{"key":"7751_CR15","volume-title":"Triple combination of MEK, BET, and CDK inhibitors significantly reduces human malignant peripheral nerve sheath tumors in mouse models","author":"S Ortega-Bertran","year":"2024","unstructured":"Ortega-Bertran S, et al. Triple combination of MEK, BET, and CDK inhibitors significantly reduces human malignant peripheral nerve sheath tumors in mouse models. Clin Cancer Res; 2024."},{"issue":"8","key":"7751_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrclinonc.2015.62","volume":"12","author":"JG Clohessy","year":"2015","unstructured":"Clohessy JG, Pandolfi PP. Mouse hospital and co-clinical trial project-from bench to bedside. Nat Rev Clin Oncol. 2015;12(8):491\u201398.","journal-title":"Nat Rev Clin Oncol"},{"key":"7751_CR17","doi-asserted-by":"publisher","first-page":"175883592092957","DOI":"10.1177\/1758835920929579","volume":"12","author":"J Fern\u00e1ndez-Rodr\u00edguez","year":"2020","unstructured":"Fern\u00e1ndez-Rodr\u00edguez J, et al. Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor. Ther Adv Med Oncol. 2020;12:1758835920929579.","journal-title":"Ther Adv Med Oncol"},{"key":"7751_CR18","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013."},{"issue":"8","key":"7751_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim S, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591\u201394.","journal-title":"Nat Methods"},{"issue":"16","key":"7751_CR20","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"7751_CR21","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, et al. Cnvkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"19","key":"7751_CR22","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1093\/bioinformatics\/btx346","volume":"33","author":"B Gel","year":"2017","unstructured":"Gel B, Serra E. karyoploteR: an R\/Bioconductor package to plot customizable genomes displaying arbitrary data. Bioinformatics. 2017;33(19):3088\u201390.","journal-title":"Bioinformatics"},{"issue":"12","key":"7751_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","volume":"20","author":"AM Tsimberidou","year":"2023","unstructured":"Tsimberidou AM, et al. Molecular tumour boards - current and future considerations for precision oncology. Nat Rev Clin Oncol. 2023;20(12):843\u201363.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"7751_CR24","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-14-3049","volume":"21","author":"AC Hirbe","year":"2015","unstructured":"Hirbe AC, et al. Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma. Clin Cancer Res. 2015;21(18):4201\u201311.","journal-title":"Clin Cancer Res"},{"issue":"7521","key":"7751_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514(7521):247\u201351.","journal-title":"Nature"},{"issue":"17","key":"7751_CR26","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-23-0749","volume":"29","author":"JL Kohlmeyer","year":"2023","unstructured":"Kohlmeyer JL, et al. CDK4\/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression. Clin Cancer Res. 2023;29(17):3484\u201397.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07751-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:56:24Z","timestamp":1773831384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07751-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7751"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07751-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HS has served on advisory boards for AstraZeneca\/Alexion. Other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"385"}}